Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare
Sandoz's Strategic Momentum in Biosimilars and Generics Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe

By João L. Carapinha

January 21, 2026

Pioneering Alzheimer's Care Innovation in Europe Alzheimer's care innovation is transforming Europe's approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 milli...